Effectiveness and cost-effectiveness of imatinib for treatment of chronic myeloid leukaemia
نویسنده
چکیده
inspected n = 213 Full text articles retrieved n = 17 Full text articles inspected n = 17 Articles for appraisal and data extraction n = 17 Excluded n = 196 Not primary research = 91 Not imatinib = 10 Not chronic phase CML = 20 Biological/preclinical/genetic studies = 46 Not first-line treatment of CML = 16 Animal studies = 2 Other = 11 (complications 9, outcome measures 2) Excluded n = 16 Biological/preclinical/genetic studies = 6 Not first-line treatment of CML = 4 Children = 1 Abstract only = 2 No control group = 3 FIGURE 4 Flowchart showing the inclusion/selection process for imatinib
منابع مشابه
The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: a systematic review.
متن کامل
738 What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukaemia (CML) after Imatinib Loses Patent Exclusivity?
We analysed and compared the cost-effectiveness of 2 strategies for treating CML patients -using imatinib first in all (altering therapy as needed in a stepwise approach) or by physician's choice, starting either imatinib or one of the approved second-generation tyrosine kinase inhibitors (TKIs) dasatinib or nilotinib. Currently, each TKI is patent-protected and commands about one-third of fron...
متن کاملNICE backs leukaemia drug after manufacturer drops price.
The National Institute for Health and Clinical Excellence has recommended nilotinib (Tasigna) for the firstline treatment of chronic myeloid leukaemia after the manufacturer agreed to reduce the price for the NHS. In final draft guidance NICE also reaffirmed the use of imatinib (Glivec) for firstline treatment of the rare condition that affects around 560 people in the UK each year. Both drugs ...
متن کاملDasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
BACKGROUND Nilotinib and dasatinib are now being considered as alternative treatments to imatinib as a first-line treatment of chronic myeloid leukaemia (CML). OBJECTIVE This technology assessment reviews the available evidence for the clinical effectiveness and cost-effectiveness of dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of Philadelphia chromosome-positi...
متن کاملEffectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision Analysis
Currently several tyrosine kinase inhibitors (TKIs) are approved for treatment of chronic myeloid leukemia (CML). Our goal was to identify the optimal sequential treatment strategy in terms of effectiveness and cost-effectiveness for CML patients within the US health care context. We evaluated 18 treatment strategies regarding survival, quality-adjusted survival, and costs. For model parameters...
متن کامل